Opinion
Video
Medical experts discuss criteria for switching GVHD treatments and how to choose between available treatment options.
Video content above is prompted by the following:
How do you establish that the patient is not responding well to steroids/is steroid-refractory?
How long should one wait before switching to a second-line treatment?
DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets
Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC
Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC
2 Commerce Drive
Cranbury, NJ 08512